A Cincinnati corporation may help make COVID-19 testing a little faster and easier.
Procter & Gamble’s novel polypropylene nasal swab collects samples from the front of the nose rather than through the long cavity between the nose and the mouth. Rhinostics, a spin-out company from Harvard University that reduces inefficiencies in laboratory workflows, has licensed the swab and will pursue Emergency Use Authorization for home collection with rPT-PCR testing for COVID-19.
The companies believe that the swab, which they say provides sample concentration of up to 30 fold over other swabs in viral transport media, will reduce lab processing time and help eliminate test shortages. Rhinostics leaders also say the swab could be adapted to test for other afflictions, like influenza.
Cincinnati-based P&G developed the swab through its personal health care business and iMFLUX, a subsidiary focused on mold design and process technology innovation for the plastics injection molding market.
“We are proud to see the P&G developed nasal swab come to market through Rhinostics efforts,” Mary Wagner, SVP at P&G and CEO of iMFLUX, says in a statement. “When we began this program, our intention was simply to help relieve bottlenecks in COVID-19 swab supply and bring a novel collection device to bear on the problem.”